✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Best Antidepressants in 2026: 10 Evidence-Backed Picks Across All Major Classes

Modern antidepressant selection is symptom-pattern-driven, comorbidity-driven, and tolerability-driven. The 2024 BAP, NICE, and CANMAT updates all converge on the same approach: pick the molecule whose side-effect profile and secondary indication best matches the patient. The 10 antidepressants in this guide cover the SSRIs that handle most cases, the SNRIs that add pain coverage, and the atypicals and TCAs that occupy specific niches.

How modern antidepressant choice is structured

For a first episode of moderate depression, an SSRI is first-line — escitalopram and sertraline carry the strongest tolerability and efficacy combination across major meta-analyses (Cipriani 2018 network meta-analysis remains the reference). When depression co-exists with chronic pain, fibromyalgia, or peripheral neuropathy, an SNRI like duloxetine adds value through its noradrenergic component. When sexual side effects are a deal-breaker, bupropion is a sexual-side-effect-free alternative. When insomnia, low appetite, or weight loss accompanies depression, mirtazapine’s sedative and orexigenic profile is therapeutic.

Treatment-resistant depression — failure of two adequate antidepressant trials — moves to combination therapy or augmentation (atypical antipsychotic add-on, lithium, T3) and requires specialist input. The medications in this guide cover first-line and second-line options. ECT, ketamine/esketamine, and TMS are options for refractory cases that go beyond what oral generics can provide.

1. Lexaheal (Escitalopram 5/10/20 mg)

Class: SSRI · Manufacturer: Healing Pharma · View product

Escitalopram is the S-enantiomer of citalopram — same mechanism (selective serotonin reuptake inhibition), refined potency, fewer dose-dependent QT effects than racemic citalopram. The Cipriani 2018 network meta-analysis ranked escitalopram top of the SSRI class on combined efficacy and tolerability. Onset 2–4 weeks for anxiety symptoms, 4–6 weeks for full antidepressant effect. Standard dose 10–20 mg once daily.

Side effects: nausea early, sexual dysfunction (anorgasmia, reduced libido — class-wide SSRI effect, ~30%+), insomnia or somnolence (variable), sweating, mild weight gain on long-term use, discontinuation syndrome on rapid stop. Less QT prolongation than citalopram but still requires caution at higher doses.

Pick for: first-line major depressive disorder, generalised anxiety disorder, panic disorder, social anxiety. Best general-purpose SSRI.

2. Citapad (Citalopram 10/20/40 mg)

Class: SSRI (racemic) · Manufacturer: Cipla · View product

Citalopram is the older racemic SSRI — escitalopram is its purified active enantiomer. Comparable efficacy at appropriate doses (citalopram 20 mg ≈ escitalopram 10 mg). The 40 mg upper limit is the FDA-set safety ceiling because of dose-dependent QT prolongation; in older patients (>60), the ceiling drops to 20 mg. Otherwise has very similar profile to escitalopram with somewhat broader sedation/activation variability.

Pick for: alternative SSRI when escitalopram is unavailable; cost-conscious continuous SSRI therapy.

3. Pexep CR (Paroxetine CR 12.5/25/37.5 mg)

Class: SSRI (controlled-release) · Manufacturer: Sun Pharma · View product

Paroxetine is the most-sedating SSRI and has weak antimuscarinic effect, which makes it more useful for the heavily anxious or agitated depression presentation than for low-energy or hypersomnic depression. The CR formulation reduces nausea and improves tolerability vs immediate-release. Significant disadvantages: more weight gain than other SSRIs, sexual dysfunction at the high end of class incidence, the most severe SSRI discontinuation syndrome (taper carefully — patients can become functionally disabled by abrupt stop), avoid in pregnancy (cardiac malformation signal in first-trimester exposure).

Pick for: severe anxiety or panic with prominent agitation, OCD, generalised anxiety disorder. Avoid in pregnancy.

4. Flunil (Fluoxetine 10/20/40/60 mg)

Class: SSRI (long half-life) · Manufacturer: Cipla · View product

Fluoxetine has the longest half-life of any SSRI (~4–6 days for parent drug, 7–15 days for active metabolite norfluoxetine). This is both an advantage (forgiving of missed doses, less discontinuation syndrome) and a disadvantage (slower to clear when switching antidepressant, longer washout before MAOI). FDA-approved indications include MDD, OCD, bulimia, premenstrual dysphoric disorder, and panic disorder. The only SSRI with strong RCT evidence in adolescent depression.

Pick for: adolescent depression, OCD, bulimia, PMDD, atypical depression with hypersomnia or low energy. Avoid combining with high-dose serotonergic agents (high MAOI washout requirement).

5. Duvanta (Duloxetine 20/30/60 mg)

Class: SNRI · Manufacturer: Sun Pharma · View product

Duloxetine is the most-prescribed SNRI globally — selective dual serotonin/noradrenaline reuptake inhibition. Standard antidepressant dose 60 mg daily; pain doses extend to 120 mg in fibromyalgia and chronic musculoskeletal pain. FDA-approved for MDD, GAD, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. Off-label use in stress urinary incontinence (where its noradrenergic effect on the urethral sphincter has measurable benefit).

Side effects: nausea (high incidence, often transient), sweating, dose-dependent BP elevation (check BP at 4 weeks then 3-monthly), urinary retention, hepatotoxicity (avoid in patients with significant alcohol use or chronic liver disease), discontinuation syndrome.

Pick for: depression with comorbid chronic pain, fibromyalgia, diabetic neuropathy, stress urinary incontinence, GAD with somatic features.

6. Bupron XL (Bupropion 150/300 mg XL)

Class: NDRI (atypical) · Manufacturer: Sun Pharma · View product

Bupropion is mechanistically distinct from SSRIs/SNRIs — selective dopamine and noradrenaline reuptake inhibition with negligible serotonergic effect. The clinical advantages: no sexual dysfunction (the most-reported reason for switching from SSRIs), no weight gain (often mild weight loss), activating profile useful in fatigued or hypersomnic depression. FDA-approved indications include MDD, seasonal affective disorder, smoking cessation (Zyban brand), and adjunct in obesity treatment (Contrave combination).

Side effects: insomnia (avoid evening dose), anxiety/agitation early in treatment, dry mouth, headache, dose-dependent seizure risk (contraindicated in eating disorders, history of seizure, withdrawal states), tachycardia.

Pick for: SSRI sexual side effects, low-energy depression, smoking cessation alongside depression treatment, weight-conscious patients, depression with prominent fatigue.

7. Mirnite (Mirtazapine 7.5/15/30 mg)

Class: Tetracyclic NaSSA (atypical) · Manufacturer: Sun Pharma · View product

Mirtazapine has a unique pharmacology — α2-adrenergic and 5-HT2/5-HT3 antagonism, which produces noradrenergic and serotonergic enhancement without the GI/sexual side-effect profile of SSRIs. Most-sedating of the modern antidepressants at low doses (paradoxically less sedating at higher doses). Stimulates appetite. The combination of sedation, weight gain, and good tolerability makes mirtazapine the antidepressant of choice in depression with insomnia, low appetite, weight loss, or significant somatic agitation.

Side effects: sedation (most patients tolerate within 2 weeks), weight gain (~2–5 kg over months), increased appetite, dry mouth, very rare agranulocytosis.

Pick for: depression with insomnia, depression with poor appetite or weight loss, elderly depression where SSRI sexual or anxiety side effects are problematic, augmentation alongside SSRI in partial responders (“California rocket fuel” — SSRI plus mirtazapine).

8. Agoprex (Agomelatine 25 mg)

Class: Melatonergic agonist + 5-HT2C antagonist (atypical) · Manufacturer: Servier-licensed generic · View product

Agomelatine is the most class-distinct antidepressant in modern use — agonist at melatonin MT1 and MT2 receptors and antagonist at 5-HT2C receptors. The downstream effect is restoration of disrupted circadian rhythms (often a feature of depression) and downstream noradrenergic and dopaminergic enhancement. Notable for absence of sexual dysfunction, absence of weight gain, absence of discontinuation syndrome, and absence of typical SSRI initial activation/anxiety.

Side effects: hepatotoxicity is the major concern — LFTs at baseline, weeks 3, 6, 12, then quarterly. Discontinue if ALT/AST >3× upper limit of normal. Avoid in significant liver disease. Otherwise very well tolerated; nausea, dizziness, headache uncommon.

Pick for: depression where SSRI side effects (sexual, weight, discontinuation) are unacceptable; depression with disrupted sleep-wake rhythm; patients with prior SSRI-induced anxiety.

9. Doxin (Doxepin 10/25/75 mg)

Class: TCA · Manufacturer: WHO-GMP certified · View product

Doxepin is a tricyclic antidepressant with the strongest H1 antihistamine activity of the class — at low doses (3–6 mg) it functions as a sleep-maintenance hypnotic with no addictive potential. At intermediate doses (25–50 mg) it provides anxiolysis and is useful in anxiety-and-pain syndromes. At high doses (100–300 mg) it’s a full TCA antidepressant with anticholinergic load. Modern use in depression has receded in favour of SSRIs/SNRIs, but doxepin survives for sleep maintenance (Silenor in the US), chronic urticaria (potent H1 + H2 effect), and adjunct anxiolysis in patients with co-existing depression and chronic itch.

Side effects: antimuscarinic (dry mouth, constipation, urinary retention, blurred vision — pronounced at high doses), sedation, orthostatic hypotension, weight gain, QT prolongation, cardiotoxic in overdose (TCAs are the most lethal antidepressant in deliberate self-harm).

Pick for: sleep-maintenance insomnia (low dose), chronic idiopathic urticaria, anxiety with somatic features, depression with severe insomnia where mirtazapine isn’t tolerated.

10. Antidep (Imipramine 25/75 mg)

Class: TCA · Manufacturer: WHO-GMP certified · View product

Imipramine is the original TCA — the molecule that defined the antidepressant class in the 1950s. Modern primary use has narrowed to: childhood enuresis (FDA-approved for nocturnal bedwetting in children >6 years; takes weeks to work, relapse on discontinuation), panic disorder (where the original Klein 1964 trial established imipramine’s anti-panic effect — predates SSRI evidence), neuropathic pain (along with amitriptyline and nortriptyline), and some chronic pain syndromes including migraine prophylaxis.

Side effects: standard TCA load — antimuscarinic, orthostatic hypotension, sedation, QT prolongation, cardiotoxic in overdose. Less sedating than amitriptyline; more cardiac caution in older patients.

Pick for: childhood enuresis, panic disorder when SSRI hasn’t worked, neuropathic pain, prophylactic migraine. Generally not first-line for depression in modern practice.

Comparison table: 10 antidepressants at a glance

Frequently asked questions

What is the best antidepressant?

For first-episode moderate depression, escitalopram and sertraline ranked highest in the 2018 Cipriani network meta-analysis on combined efficacy and tolerability. But the “best” antidepressant depends on the patient — chronic pain pushes toward SNRIs, sexual side effects push toward bupropion or agomelatine, insomnia pushes toward mirtazapine. Pick by symptom pattern and side-effect profile match, not by single-metric ranking.

How long do antidepressants take to work?

Initial improvement (sleep, appetite) often appears in 1–2 weeks. Full antidepressant effect develops at 4–6 weeks. If there’s no response at all by 4 weeks at adequate dose, dose escalation or switch to a different class is reasonable. Anxiety-symptom relief sometimes lags depression-symptom relief; SSRIs can transiently increase anxiety in the first 1–2 weeks before settling.

How long should I stay on an antidepressant?

For a first episode, treatment continues for 6–12 months after symptom remission, then taper. For recurrent depression (two prior episodes), maintenance for 2 years minimum. For three or more recurrent episodes, indefinite maintenance is often considered. Stopping medication when feeling well can lead to relapse; the decision should be planned with a clinician, not unilaterally on the basis of feeling better.

Can I drink alcohol on antidepressants?

Limited light drinking (1–2 standard drinks) is generally tolerable on most antidepressants. Heavy drinking compounds depression, impairs antidepressant response, and increases side effects. Specific cautions: bupropion’s seizure risk is amplified with alcohol withdrawal; TCAs and alcohol are markedly additive on sedation and cognitive impairment; agomelatine’s hepatotoxicity is amplified with alcohol; SSRI-induced GI bleeding risk is amplified with NSAIDs and alcohol.

Will antidepressants change my personality?

No — but they can change the depressive distortion of personality. Depression can blunt emotional range and interest; effective treatment restores access to baseline emotional experience. The “emotional blunting” reported by some SSRI users (~10–20%) is a separate phenomenon — usually subsides with dose reduction or switch to a non-serotonergic agent like bupropion or agomelatine.

What is discontinuation syndrome?

A constellation of symptoms (flu-like aches, dizziness, “brain zaps,” irritability, insomnia, vivid dreams) on rapid stop or rapid taper of an antidepressant. Most pronounced with paroxetine (short half-life, high receptor occupancy) and venlafaxine. Least pronounced with fluoxetine (long half-life self-tapers). Standard taper schedules halve the dose every 2–4 weeks; some patients need slower hyperbolic taper.

Are SSRIs addictive?

No — SSRIs are not addictive in the classical sense. There’s no euphoria, no escalating tolerance, no compulsive seeking. There IS physical adaptation that produces discontinuation syndrome on rapid stop, but that’s different from addiction. The confusion comes from mistaking discontinuation syndrome for withdrawal craving.

Can antidepressants cause weight gain?

Class-dependent. Mirtazapine causes notable gain (2–5 kg). Paroxetine and TCAs cause moderate gain. SSRIs (escitalopram, citalopram, sertraline) cause mild gain over months. Bupropion and agomelatine are generally weight-neutral or weight-losing. Choice can be tailored to weight priority.

Related guides: All mental health medications · Best antibiotics 2026 · Best BP medications 2026

For patients needing an atypical antipsychotic as an antidepressant adjunct, see our detailed guide to Seroquel generic (quetiapine) — available from 25 mg IR to 400 mg SR.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.